kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
635
JPY
-23
(-3.50%)
Mar 13, 3:30 pm JST
3.98
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
632
Mar 13, 7:17 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.90
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Mar 13, 2026
Opening Mar 13, 9:06 am
630 JPY 3.96 USD
Previous Close Mar 12
658 JPY 4.13 USD
High Mar 13, 9:12 am
640 JPY 4.02 USD
Low Mar 13, 9:07 am
626 JPY 3.93 USD
Volume
183,500
Trading Value
0.12B JPY 0.73M USD
VWAP
631.52 JPY 3.96 USD
Minimum Trading Value
63,500 JPY 398 USD
Market Cap
0.03T JPY 0.16B USD
Number of Trades
445
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
431
1-Year High Apr 22, 2025
11,342
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 325,900 604,100 1.85
Feb 27, 2026 303,000 593,700 1.96
Feb 20, 2026 258,100 477,200 1.85
Feb 13, 2026 246,700 482,400 1.96
Feb 6, 2026 255,100 519,100 2.03
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.